Buscar en
Cirugía Cardiovascular
Toda la web
Inicio Cirugía Cardiovascular Efficacy and safety of cardiac sympathetic denervation for refractory ventricula...
Información de la revista
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
101
Case Report
Acceso a texto completo
Efficacy and safety of cardiac sympathetic denervation for refractory ventricular arrhythmias: Experience of a Colombian hospital
Eficacia y seguridad de la simpatectomía cardiaca para el tratamiento de las arritmias ventriculares refractarias: experiencia de un centro colombiano
Visitas
101
Nicolas Arredondo-Moraa,b,
Autor para correspondencia
nicolasarredondom@hotmail.com

Corresponding author.
, Oscar Rincón-Barbosaa,b, Carlos A. Rodríguez-Sabogala,b
a Central Military Hospital's Thorax Surgery Department, Bogota DC, Colombia
b Nueva Granada Military University, Bogota DC, Colombia
Este artículo ha recibido
Recibido 30 agosto 2023. Aceptado 09 noviembre 2023
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Tablas (1)
Table 1. Patient's preoperative characteristics and postoperative outcomes.
Abstract

Left or bilateral cardiac sympathetic denervation is employed as a final option for treating pharmacologically refractory ventricular arrhythmias of various etiologies. In this study, we share our experience with bilateral cardiac denervation. A total of 6 patients (mean age 73.8 years±6.5 years, mean LVEF 37±8.3%), between 2021 and 2022, with sarcoidosis or ischemic heart disease underwent bilateral cardiac denervation due to electrical storm despite prior treatments. It was achieved complete resolution of ventricular arrhythmias in 100% of cases, with no recurrence of cardiac device shocks and no mortalities, neither cases of pneumothorax, Horner's syndrome, or other complications. Therefore, it was concluded that in this study, bilateral cardiac denervation was effective for treatment of refractory ventricular arrhythmias. Further larger studies are required to confirm these findings.

Keywords:
Cardiac sympathetic denervation
Sympathectomy
Refractory ventricular arrhythmias
Intractable ventricular arrhythmias
Electrical storm
Resumen

La simpatectomía cardiaca izquierda o bilateral es usada como opción de última línea en el tratamiento de arritmias ventriculares refractarias de diferentes etiologías. En el siguiente texto, presentamos nuestra experiencia con la denervación cardiaca bilateral. En total, seis pacientes (edad promedio 73,8 ± 6,5, fracción de eyección del ventrículo izquierdo (FEVI) promedio 37 ± 8,3%) entre los años 2021 y 2022, con enfermedad cardiaca isquémica o sarcoidosis, fueron llevados a simpatectomía cardiaca bilateral por tormenta arrítmica que fue refractaria a otros tratamientos. Se consiguió una resolución completa de las arritmias ventriculares en 100% de los casos, sin recurrencias de descargas de los dispositivos cardiacos implantables y sin mortalidades reportadas. Tampoco se observaron situaciones de neumotórax, síndrome de Horner u otras complicaciones. Por lo anterior, pudimos concluir que, en este estudio, la simpatectomía cardiaca bilateral fue efectiva y segura para el tratamiento de las arritmias ventriculares refractarias. Se requieren estudios más grandes y comparativos para confirmar los hallazgos.

Palabras clave:
Denervación simpática cardiaca
Simpatectomía
Arritmias ventriculares refractarias
Arritmias ventriculares intratables
Tormenta eléctrica
Texto completo
Introduction

More than 100 years ago, Romanian oncologic surgeon Thomas Jonnesco performed the first left cardiac denervation in 1916, but he only published the case report in 1921.1 The first bilateral cardiac sympathetic denervation was performed in 1962, resulting in prolonged QRS normalization.2

The sympathetic postganglionic fibers of the superior thoracic ganglia innervate the heart and play an important role in maintaining arrhythmias.2 Other therapeutic options for blocking the heart's sympathetic signaling, such as stellate ganglion block and thoracic epidural anesthesia, have limited effects due to the short half-life of local anesthetics.2

Nowadays, left or bilateral cardiac sympathetic denervation is used for various types of ventricular arrhythmias of different etiologies, including channelopathies, long QT syndrome, polymorphic ventricular tachycardia, and many structural heart diseases like chagasic, sarcoidosis, hypertensive, and ischemic heart disease.1

In this paper, we present our case series of bilateral cardiac sympathetic denervation and discuss the important aspects to consider for the procedure's efficacy and complications.

Methods and results

We present a case series of bilateral cardiac sympathetic denervation procedures performed in our hospital between 2021 and 2022.

In each case, we used a two-port thoracoscopic approach (VATS) without selective intubation. We located a 5mm axillary port and another 5mm peri areolar port. We performed a bilateral T2–T4 sympathectomy by cutting the Kuntz nerves and preserving the stellate ganglion by making the proximal cut with scissors, thus avoiding diathermy injury. At the end of the procedure, we evacuated the pneumothorax with a Nelaton catheter, and none of the patients required a tube thoracostomy.

In Table 1, we show the epidemiological patient characteristics, previous failure procedures, and outcomes. We enrolled six patients aged 73.8 years (±6.5 years), all of them men, with sarcoidosis or ischemic heart disease. They presented ventricular arrhythmias with an electrical storm. Their left ventricular ejection fraction was 37% (±8.3%). Two of them had previously failed catheter ablation, and the other two patients had a previous Stellate ganglion block. All of the patients resolved the electrical storm during hospitalization in the postoperative period, and they did not present electrical shocks from their devices during follow-up.

Table 1.

Patient's preoperative characteristics and postoperative outcomes.

Number  Age  Gender  Pathological history  Cardiomyopathy etiology  Revascularization  LVEF  Device  Arrhythmia  Previous procedure  Surgical complications  Arrhythmia resolution 
62  DyslipidemiaArterial hypertension  Chagasic  No  38%  ICD  VT  Ablation  No  Yes 
81  CKDArterial hypertensionCOPDOSAHSHypothyroidismObesity  Ischemic  No  38%  ICD  VT  Stellate ganglion block  No  Yes 
75  OSAHSHypothyroidismCKD  Ischemic  No  35%  ICD  VT  No  No  Yes 
78  DMArterial hypertensionHypothyroidismCKD  Ischemic  No  28%  ICD  –  Ablation  No  Yes 
72  Arterial hypertension  Ischemic  Yes  52%  Pacemaker  VT  No  No  Yes 
75  CKDArterial hypertensionDMDyslipidemiaObesity  Chagasic  Yes  31%  ICD  VT  Stellate ganglion block  No  Yes 

CKD: chronic kidney disease; DM: diabetes mellitus; OSAHS: obstructive sleep apnea–hypopnea syndrome; ICD: implantable cardiac device; VT: ventricular tachycardia.

We did not observe any acute complications such as pneumothorax, hemothorax, or vascular lesions. Additionally, none of the patients presented chronic complications such as sweating pattern changes, Horner syndrome, or hyperalgesia.

Discussion

Traditionally, cardiac denervation has been used as a last resort for the treatment of pharmacologically refractory ventricular arrhythmias and after failing other procedures such as catheter cardiac ablation, stellate ganglion block, and thoracic epidural anesthesia. However, in our experience, cardiac sympathetic denervation was a safe and effective procedure with no complications, little morbidity, no mortalities, and a 100% efficacy rate for complete arrhythmia resolution, without cardiac device shocks recurrence or arrhythmic episodes detected and without reported complications. This could be explained by the surgical technique used, performing the procedure bilaterally, preserving the stellate ganglion, evacuating the residual pneumothorax at the end of the procedure without the use of thoracostomies. Nevertheless, contradictory results can be found in the literature.

Murtaza et al. published a meta-analysis in which they reported a pooled non-recurrence rate of ventricular tachycardias after Cardiac Sympathetic Denervation of all causes of arrhythmias to be 60%, although with high heterogeneity (I2=43%).3 Additionally, Shah et al.4 and Chihara et al.,5 in their systematic reviews, reported complete arrhythmia resolution rates of 53–100%4 and 52.4%,5 respectively.

This significant variability in the success outcomes of the procedure may be attributed to the inclusion of patients who underwent only left sympathectomy, as in the case series of König et al.,6 Cai et al.,7 and Prabhu et al.,8 which reported a complete resolution of arrhythmias of 38%, 42%, and 22%, respectively. In comparison, series such as Okada et al.,9 Téllez et al.,10 or even our own experience, demonstrated success rates of 80%, 92%, and 100%, respectively, by including only bilateral cardiac denervation.

However, it is important to highlight that in other series where only bilateral denervation were included, such as in the study by Lee et al.,11 recurrence rates as low as 46% were reported, which raises questions. Additionally, in the systematic review by Chihara et al.,5 they report complete resolution of arrhythmias defined as the absence of cardiac device discharges after denervation, with rates of 66.5% and 65% with or without stellate ganglion preservation, compared to 63.8% with left denervation alone.

According to Vaseghi et al.,12 patients with bilateral Cardiac Sympathetic Denervation experienced longer sustained VT (ventricular tachycardia) or implantable cardioverter-defibrillator (ICD) shock-free and orthotopic heart transplantation (OHT)-free survival in comparison to those with left CSD alone. However, left CSD was not identified as an independent factor associated with the recurrence of ICD shocks.

When analysis was restricted to only arrhythmias caused by conditions other than Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) and Long QT Syndrome (LQTS), the pooled VT non-recurrence rate was 50% (range 41–58%, I2=5%).12

Additionally, Vaseghi et al.12 described poor prognostic factors for complete arrhythmia resolution after cardiac denervation, including a worse NYHA classification, use of more than one antiarrhythmic drug, and a ventricular tachycardia cycle lasting more than 400ms. On the other hand, patients with a history of bilateral cardiac sympathetic denervation had more free-shock time and transplant-free survival compared to only left cardiac sympathetic denervation (p=0.014), highlighting the importance of bilateral denervation.12

In view of all the previously mentioned aspects, the importance of comparative studies is highlighted in order to determine the superiority of bilateral denervation over left denervation alone.

Regarding surgical complications, the most commonly reported one was pneumothorax in 5%4 and 5.5%5 of cases, even without reporting any events as in our series, omitting the use of thoracostomies. The majority of cases did not necessitate further treatment.

Horner's syndrome was reported in 3%4 and 4.3%5 of cases, which resolved spontaneously in most instances. The latter complication could be avoided by preserving the stellate ganglion, without compromising the surgery's effectiveness. Other more severe complications, such as hemothorax, vascular injuries, and brachial plexus injuries, occurred in less than 1% of cases each, establishing it as a safe procedure.

Conclusions

Cardiac sympathectomy is a safe procedure, with mostly self-resolving minor complications and variable effectiveness for complete arrhythmia resolution. Comparative studies are needed to assess the necessity of bilateral procedures or to identify poor prognostic factors. Additionally, comparative studies with other procedures, such as catheter ablation, need to be conducted before considering sympathectomy as a first-line treatment.

Ethical disclosuresProtection of human and animal subjects

The authors declare that no experiments were performed on humans or animals for this investigation.

Confidentiality of data

The authors declare that no patient data appears in this article.

Right to privacy and informed consent

The authors declare that no patient data appears in this article.

Ethical considerations

As a descriptive and retrospective study in which only medical records were reviewed and the identity and patients’ data will be protected, it is considered a non-risk research, therefore informed consents are not required.

Data availability statement

The articles that support the findings of this literature systematic review are available in the databases (PubMed, Embase, and Scopus) and can be accessed through a license. Regarding the patients’ clinical histories in the case series, to acquire additional information or their respective verification, please contact the correspondence author.

Funding

None.

Conflict of interest

None.

References
[1]
P.J. Schwartz, G.M. De Ferrari, L. Pugliese.
Cardiac sympathetic denervation 100 years later: Jonnesco would have never believed it.
Int J Cardiol, 237 (2017), pp. 25-28
[2]
S.M. Kochav, H. Garan, L.A. Gorenstein, E.Y. Wan, H. Yarmohammadi.
Cardiac sympathetic denervation for the management of ventricular arrhythmias.
J Interv Card Electrophysiol, 65 (2022), pp. 813-826
[3]
G. Murtaza, S.P. Sharma, K. Akella, M.K. Turagam, D.G.D. Rocca, D. Lakkireddy, et al.
Role of cardiac sympathetic denervation in ventricular tachycardia: a meta-analysis.
Pacing Clin Electrophysiol, 43 (2020), pp. 828-837
[4]
R. Shah, F. Assis, N. Alugubelli, D.R. Okada, R. Cardoso, K. Shivkumar, et al.
Cardiac sympathetic denervation for refractory ventricular arrhythmias in patients with structural heart disease: a systematic review.
Heart Rhythm, 16 (2019), pp. 1499-1505
[5]
R.K. Chihara, E.Y. Chan, L.M. Meisenbach, M.P. Kim.
Surgical cardiac sympathetic denervation for ventricular arrhythmias: a systematic review CME.
Method DeBakey Cardiovasc J, 17 (2021), pp. 24
[6]
S. König, T. Schröter, M.A. Borger, L. Bertagnolli, S. Nedios, A. Darma, et al.
Outcomes following cardiac sympathetic denervation in patients with structural heart disease and refractory ventricular arrhythmia.
EP Europace, 24 (2022), pp. 1800-1808
[7]
C. Cai, M. Dai, Y. Tian, P. Zhang, E.D. Wittwer, R.H. Rho, et al.
Electrophysiologic effects and outcomes of sympatholysis in patients with recurrent ventricular arrhythmia and structural heart disease.
J Cardiovasc Electrophysiol, 30 (2019), pp. 1499-1507
[8]
M.A. Prabhu, S.B.V. Prasad, S.P. Abhilash, A. Thajudeen, R B.K.N. Namboodiri.
Left sympathetic cardiac denervation in managing electrical storm: acute outcome and long term follow up.
J Interv Card Electrophysiol, 47 (2016), pp. 285-292
[9]
D.R. Okada, F.R. Assis, N.A. Gilotra, J.S. Ha, R.D. Berger, H. Calkins, et al.
Cardiac sympathectomy for refractory ventricular arrhythmias in cardiac sarcoidosis.
Heart Rhythm, 16 (2019), pp. 1408-1413
[10]
L.J. Téllez, J.C. Garzón, E.E. Vinck, J.D. Castellanos.
Video-assisted thoracoscopic cardiac denervation of refractory ventricular arrhythmias and electrical storms: a single-center series.
J Cardiothorac Surg, 14 (2019), pp. 17
[11]
A.C.H. Lee, R. Tung, M.K. Ferguson.
Thoracoscopic sympathectomy decreases disease burden in patients with medically refractory ventricular arrhythmias.
Interact Cardiovasc Thorac Surg, 34 (2022), pp. 783-790
[12]
M. Vaseghi, P. Barwad, F.J. Malavassi Corrales, H. Tandri, N. Mathuria, R. Shah, et al.
Cardiac sympathetic denervation for refractory ventricular arrhythmias.
J Am Coll Cardiol, 69 (2017), pp. 3070-3080
Copyright © 2023. Sociedad Española de Cirugía Cardiovascular y Endovascular
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos